This meta-analysis has several strengths: (1) Only RCTs were included, so this meta-analysis eliminated the potential control group biases; (2) The large sample size of the 6 included trials allowed us to quantitatively evaluate the GLP-1 receptor agonist effects in T2DM patients; (3) A wide range of patient characteristics was represented, which ensured a comprehensive assessment of the effect of GLP-1 receptor agonists in the treatment of patients with T2DM. Here, GLP1R is linked to type 2 diabetes mellitus.